Skip to main content

Table 1 Patients previously reported with goblet cell carcinoid in the rectum

From: Goblet cell carcinoid of the rectum: a case report

No. Author Year Age M/F Coexisting component Tumor depth Synchronous metastasis Treatment Adjuvant chemotherapy Site of recurrence Treatment of recurrence Prognosis (months)
1 Ishii [13] 2001 71 M Typical carcinoid, WDA T4b Regional lymph node Miles’ operation None Subcutaneous, testis None Died (9)
2 Kato [14] 2002 44 M None T3 None Total colectomy (accompanied by UC) None Liver, brain, peritoneum Right lobectomy of the liver, intraperitoneal administration of CDDP Died (39)
3 Wakahara [15] 2010 58 M Typical carcinoid T4b Pelvic lymph node Total pelvic exenteration, LLND 5-FU, LV Groin and pelvic lymph node Lymphadenectomy Alive (> 60)
4 Yamabuki [7] 2011 75 M None T2 Regional lymp node Miles’ operation None Lung FOLFOX Alive (15)
5 Kang[16] 2016 46 F None T1 None Low anterior resection None None None Alive (10)
6 Present patient 2020 77 M Wda T3 None Miles’ operation None Liver FOLFOX+BV, CapeOX+BV, IRIS+BV Alive (27)
  1. WDA well-differenciated adenocarcinoma; n.d. not described; UC ulcerative colitis; LLND lateral lymph node dissection; CDDP cisplatin, 5-FU; LV fluorouracil and leucovorin; FOLFOX 5-fluorouracil, leucovorin, oxaliplatin; BV bevacizumab; CapeOX capecitabine + oxaliplatin; IRIS irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate); M male; F female